Stacey F Jones

US Patent:

8221991, Jul 17, 2012

Filed:

Sep 8, 2010

Appl. No.:

12/877195

Inventors:

Steven A. Kliewer - Cary NC, US
Stacey A. Jones - Wake Forest NC, US
Timothy M. Willson - Durham NC, US

Assignee:

GlaxoSmithKline LLC - Philadelphia PA

International Classification:

G01N 33/53

US Classification:

435 72, 435 691

Abstract:

The present invention relates to a novel human orphan nuclear receptor that binds to a cytochrome P-450 monooxygenase (CYP) promoter and that is activated by compounds that induce CYP gene expression. The invention further relates to nucleic acid sequences encoding such a receptor, to methods of making the receptor and to methods of using the receptor and nucleic acid sequences encoding same. The invention also relates to non-human animals transformed to express the human receptor and to methods of using such animals to screen compounds for drug interactions and toxicities.

US Patent:

20040038862, Feb 26, 2004

Filed:

Jan 28, 2003

Appl. No.:

10/343289

Inventors:

Bryan Goodwin - Durham NC, US
Stacey Jones - Durham NC, US
Steven Kliewer - Durham NC, US
Patrick Maloney - Durham NC, US

International Classification:

G01N033/53
G01N033/567
A61K038/17

US Classification:

514/002000, 435/007200

Abstract:

Abstract: Methods for identifying compounds that modulate bile acid synthesis by assessing their ability to act as ligands for short heterodimerizing partner-1 or liver receptor homologue-1 are provided. Also provided are compositions containing these ligands as well as methods for administering these compositions to modulate bile acid synthesis and cholesterol and lipid homeostasis.

US Patent:

20050107475, May 19, 2005

Filed:

Mar 19, 2003

Appl. No.:

10/507082

Inventors:

Stacey Jones - Durham NC, US
Steven Kliewer - Dallas TX, US
Traci Mansfield - New Haven CT, US

International Classification:

A61K031/47
A61K031/19

US Classification:

514571000

Abstract:

Treatment of human hepatocytes with farnesoid X receptor (FXR) agonists resulted in increased expression of FGF-19. Methods of using FXR agonists to alter cell metabolism, and in pharmaceutical weight loss methods, are described.

US Patent:

20070015796, Jan 18, 2007

Filed:

Sep 10, 2004

Appl. No.:

10/572974

Inventors:

Stacey Jones - Durham NC, US
Yaping Liu - Durham NC, US
John Moore - Durham NC, US

Assignee:

SMITHKLINE BEECHAM CORPORATION - Philadelphia PA

International Classification:

A61K 31/4439
A61K 31/42

US Classification:

514340000, 514378000

Abstract:

Methods for the treatment of fibrosis, including liver fibrosis, via administration of FXR agonists are provided.

US Patent:

20080096239, Apr 24, 2008

Filed:

Jun 22, 2007

Appl. No.:

11/766871

Inventors:

Steven Kliewer - Research Triangle Park NC, US
Stacey Jones - Research Triangle Park NC, US
Timothy Willson - Research Triangle Park NC, US

Assignee:

SMITHKLINE BEECHAM CORPORATION - Philadelphia PA

International Classification:

C12Q 1/02
C07H 21/00
C07K 14/005
C12N 15/63
C12P 21/02

US Classification:

435029000, 435320100, 435069100, 530324000, 530350000, 536023400

Abstract:

The present invention relates to a novel human orphan nuclear receptor that binds to a cytochrome P-450 monoxygenase (CYP) promoter and that is activated by compounds that induce CYP gene expression. The invention further relates to nucleic acid sequences encoding such a receptor, to methods of making the receptor and to methods of using the receptor and nucleic acid sequences encoding same. The invention also relates to non-human animals transformed to express the human receptor and to methods of using such animals to screen compounds for drug interactions and toxicities.

US Patent:

20110021475, Jan 27, 2011

Filed:

Jul 22, 2010

Appl. No.:

12/841611

Inventors:

Stacey Ann Jones - Durham NC, US
Yaping Liu - Durham NC, US
Joh Tomlin Moore - Durham NC, US

International Classification:

A61K 31/575
A61K 31/42
A61P 1/16
A61P 35/00

US Classification:

514171, 514378

Abstract:

Methods for the treatment of fibrosis, including liver fibrosis, via administration of FXR agonists are provided.

US Patent:

20120283412, Nov 8, 2012

Filed:

Jul 16, 2012

Appl. No.:

13/550211

Inventors:

Steven A. Kliewer - Cary NC, US
Stacey A. Jones - Wake Forest NC, US
Timothy M. Willson - Durham NC, US

International Classification:

C07K 14/705
C12N 15/12
C12N 1/21
C12P 21/00
C12N 5/10
C12N 1/19
C07K 19/00
C12N 15/63

US Classification:

530350, 536 235, 4353201, 435 691, 435325, 435348, 4352542, 4352523, 435370

Abstract:

The present invention relates to a novel human orphan nuclear receptor that binds to a cytochrome P-450 monooxygenase (CYP) promoter and that is activated by compounds that induce CYP gene expression. The invention further relates to nucleic acid sequences encoding such a receptor, to methods of making the receptor and to methods of using the receptor and nucleic acid sequences encoding same. The invention also relates to non-human animals transformed to express the human receptor and to methods of using such animals to screen compounds for drug interactions and toxicities.

US Patent:

7238491, Jul 3, 2007

Filed:

Mar 26, 1999

Appl. No.:

09/276935

Inventors:

Steven A. Kliewer - Cary NC, US
Stacey A. Jones - Wake Forest NC, US
Timothy M. Willson - Durham NC, US

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

G01N 33/53

US Classification:

435 72, 435 78, 435 24

Abstract:

The present invention relates to a novel human orphan nuclear receptor that binds to a cytochrome P-450 monooxygenase (CYP) promoter and that is activated by compounds that induce CYP gene expression. The invention further relates to nucleic acid sequences encoding such a receptor, to methods of making the receptor and to methods of using the receptor and nucleic acid sequences encoding same. The invention also relates to non-human animals transformed to express the human receptor and to methods of using such animals to screen compounds for drug interactions and toxicities.